| Literature DB >> 34947656 |
Yong Chang1, Ning Xia1, Yaliang Huang1, Zhifang Sun1, Lin Liu1.
Abstract
The physiochemical properties of nanomaterials have a close relationship with their status in solution. As a result of its better simplicity than that of pre-assembled aggregates, the in situ assembly of nanomaterials has been integrated into the design of electrochemical biosensors for the signal output and amplification. In this review, we highlight the significant progress in the in situ assembly of nanomaterials as the nanolabels for enhancing the performances of electrochemical biosensors. The works are discussed based on the difference in the interactions for the assembly of nanomaterials, including DNA hybridization, metal ion-ligand coordination, metal-thiol and boronate ester interactions, aptamer-target binding, electrostatic attraction, and streptavidin (SA)-biotin conjugate. We further expand the range of the assembly units from nanomaterials to small organic molecules and biomolecules, which endow the signal-amplified strategies with more potential applications.Entities:
Keywords: electrochemical biosensors; hybridization; nanomaterials; peptide; self-assembly; streptavidin
Year: 2021 PMID: 34947656 PMCID: PMC8705329 DOI: 10.3390/nano11123307
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1(A) Schematic representation of the principle of the dnGOPs-based electrochemical detection of DNA [37]. Copyright 2014 American Chemical Society. (B) Schematic representation of DNA-AuNPs assembled polymeric network amplified electrochemical biosensor for kinase activity detection [38]. Copyright 2014 American Chemical Society.
Figure 2Schematic representation of cascade amplification of DSN-assisted target recycling and CHA reaction and in situ self-assembly of AuNP networks on electrodes for label-free electrochemical detection of miR-141 in signal-on mode [39]. Copyright 2018 American Chemical Society.
Figure 3Schematic representation of ultrasensitive and label-free electrochemical detection of miRNA-199a based on in situ generated AgNCs by coupling TAPNR with HCR amplifications [49]. Copyright 2015 American Chemical Society.
Figure 4(A) Schematic representation of the electrochemical Hg2+ sensor based on Ag-T nanoprobes [28]. Copyright 2015 American Chemical Society. (B) Schematic representation of electroactive Au@Ag NP assembly driven signal amplification for ultrasensitive chiral discrimination of D-/L-Trp [59]. Copyright 2019 American Chemical Society.
Figure 5Schematic representation of the proposed electrochemical strategy for miRNAs detection based on MPBA-induced in situ formation of AgNPs aggregates as labels [67]. Copyright 2017 Elsevier B.V.
Figure 6Schematic representation of the proposed electrochemical strategies for protein kinase detection based on the in situ formation of the AgNPs aggregates as labels. In the first design (A), ATP-S was used as the co-substrate. In the second design (B), ATP was used as the co-substrate, and tyrosinase was used to convert monophenol into o-diphenol [68]. Copyright 2017 Elsevier B.V.
Figure 7Schematic representation of the biosensor for the detection of wild-type p53 protein by the in situ formation of AgNPs networks for signal amplification [70]. Copyright 2020 Elsevier B.V.
Figure 8(A) Schematic representation of the electrochemical method for the selective detection of AβOs using AgNPs as the redox reporters and Ad-PrP(95−110) as the receptor [78]. Copyright 2016 American Chemical Society. (B) Schematic illustration of the electrochemical method for hCG detection using a peptide probe as the receptor of hCG and the inducer of AuNPs assembly [79]. Copyright 2017 Elsevier B.V.
Figure 9Schematic representation of (A) the co-assembly of P3 and CNDs and (B) the principle of the analysis of TG2 [81]. Copyright 2021 American Chemical Society.
Figure 10(A) Self-assembly of biotin–Phe monomers into biotin–FNP and the in situ formation of SA–biotin–FNP networks on the electrode surface. (B) Schematic representation of the biosensor for assay of caspase-3 activity via the signal amplification by SA–biotin–FNP networks [85]. Copyright 2020 Elsevier B.V.
Figure 11(A) Schematic representation of the principle of the dnGOPs-based electrochemical detection of DNA [89]. Copyright 2017 American Chemical Society. (B) Schematic representation of “signal-on” electrochemical biosensing of thrombin activity [93]. Copyright 2020 American Chemical Society.
Figure 12Schematic representation of the surface-tethered electrochemical analysis for caspase-3 detection [96]. Copyright 2021 American Chemical Society.
Analytical performances of different electrochemical biosensors based on the in situ assembly of nanomaterials and molecules for the signal enhancement.
| Interaction | Nanomaterials | Target | Detection Range | Detection Limit | Ref. |
|---|---|---|---|---|---|
| DNA hybridization | DNA-AuNPs | lysozyme | 1 pM–1 nM | 0.32 pM | [ |
| DNA-AgNPs | PDGF and thrombin | 5 pg/mL–1000 ng/mL | 1.6 pg/mL | [ | |
| DNA-AuNPs | PKA | 0.03–40 U/mL | 0.03 U/mL | [ | |
| DNA-AuNPs | miR-141 | 0.1 fM–10 nM | 25.1 aM | [ | |
| DNA-CeO2 | VEGF | 1 fg/mL–0.1 ng/mL | 0.27 fg/mL | [ | |
| Thi-modified DNA-Fe3O4 NPs and Fc-CHO-modified DNA-Fe3O4 NPs | miR-141 and miR-21 | 1 fM–1 nM | 0.44 fM for miR-141 and 0.46 fM for miR-21 | [ | |
| DNA-AgNPs | miR-17-5p | 100 aM–100 pM | 2 aM | [ | |
| DNA-based electrostatic interaction | Ag@Au CSNPs | Hg2+ | 10 pM–2.5 nM | 3.6 pM | [ |
| CTAB-capped AgNPs | PSA | 0.1 pg/mL–75 ng/mL | 0.033 pg/mL | [ | |
| AuNPs | DNA | 15 pM–1.0 nM | 2.6 pM | [ | |
| DNA-based in situ metallization | AgNCs | DNA | 0.2 fM–1 pM | 0.16 fM | [ |
| AgNCs | miR-199a | 1.0 fM–0.1 nM | 0.64 fM | [ | |
| AgNCs | methyltransferase | 0.02–10 U/mL | 0.0073 U/mL | [ | |
| AgNPs | Pb2+ | 1 pM–100 nM | 0.24 pM | [ | |
| AgNPs | Type b3a2 | 10 fM–10 nM | 0.56 fM | [ | |
| AgNCs | HAT | 0.5–100 nM | 0.49 nM | [ | |
| CuNPs | folate receptor | 0.01–100 ng/mL | 3 pg/mL | [ | |
| CuNCs | miR-21 | 10 pM–0.1 fM | 10 aM | [ | |
| Metal ion–ligand coordination | thymine-modified AgNPs | Hg2+ | 50 pM–50 nM | 5 pM | [ |
| MBA-modified AgNPs | Cu2+ | 0.1–100 nM | 0.08 nM | [ | |
| MPA-modified AgNPs | Cr3+ | 200–5000 ppb | 278 ppb | [ | |
| Thymine-modified UCNPs | Hg2+ | 10 pM–100 nM | 0.4 pM | [ | |
| Au@Ag NPs | D-tryptophan | 5 pM–1 nM | 1.21 pM | [ | |
| L-cysteine-modified AuNPs | lipopolysaccharide | 1.0–10 pg/mL | 0.033 pg/mL | [ | |
| Metal–thiol and boronate ester interactions | citrate-capped AgNPs | tyrosinase | 0.001–0.5 mU/mL | 0.1 mU/mL | [ |
| citrate-capped AgNPs | thrombin | 0.025–5 ng/mL | 0.02 ng/mL | [ | |
| citrate-capped AgNPs | H2O2 | 1 nM–0.6 μM | Not reported | [ | |
| citrate-capped AgNPs | miR-21 | 0.1–50 fM | 20 aM | [ | |
| citrate-capped AgNPs | tyrosine kinase | 0.1–25 ng/mL | 0.1 ng/mL | [ | |
| citrate-capped AgNPs | PSA | 0.5–200 pg/mL | 0.2 pg/mL | [ | |
| citrate-capped AgNPs | wild-type p53 | 0.1–100 pM | 0.1 pM | [ | |
| Peptide-induced assembly | citrate-capped AuNPs | PKA | 0.01–1 U/mL | 20 mU/mL | [ |
| citrate-capped AuNPs | DPP-IV | 0.001–0.5 mU/mL | 0.55 µU/mL | [ | |
| citrate-capped AgNPs | AβO | 0.01–200 nM | 6 pM | [ | |
| citrate-capped AgNPs | AβO | 20 pM–100 nM | 8 pM | [ | |
| citrate-capped AuNPs | hCG | 0.001–0.2 IU/mL | 0.6 mIU/mL | [ | |
| citrate-capped AgNPs | hCG | 0.001–0.2 IU/mL | 0.4 mIU/mL | [ | |
| Carbon nanodots | transglutaminase 2 | 1 pg/mL–50 ng/mL | 0.25 pg/mL | [ | |
| SA–biotin interaction | biotin-FNPs | aflatoxin B1 | 0.05–3 pg/mL | Not reported | [ |
| biotin-FNPs | caspase-3 | 1–125 pg/mL | 1 pg/mL | [ | |
| biotin-FNPs | miR-21 | 0.1–250 fM | 0.1 fM | [ | |
| In situ assembly of small molecules and biomolecules | Fc derivate | DNA | 1.0 fM–1.0 nM | 0.47 fM | [ |
| Fc derivate | PKA | 0–140 mU/mL | 1.63 mU/mL | [ | |
| Fc derivate | DNA | 0.1 fM–0.1 nM | 0.072 fM | [ | |
| Fc derivate | DNA | 10 aM–10 pM | 3.2 aM | [ | |
| Fc derivate | PKA | 0–140 mU/mL | 1.02 mU/mL | [ | |
| Fc derivate | trypsin | 25–175 μU/mL | 18.2 μU/mL | [ | |
| Fc derivate | thrombin | 10–250 μU/mL | 2.7 μU/mL | [ | |
| Fc derivate | CYFRA 21-1 | 1 pg/mL–1 μg/mL | 9.08 fg/mL | [ | |
| Fc-labeled peptide | AβO | 0.005–5 μM | 0.6 nM | [ | |
| (SA–biotin–peptide–biotin)n | caspase-3 | 0–50 pg/mL | 0.2 pg/mL | [ | |
| (SA–biotin–DNA–biotin)n | miR-21 | 0.01–2.5 fM | 10 aM | [ | |
| (SA–biotin–DNA–biotin)n | telomerase | 20–5000 cells/mL | 20 cells/mL | [ |
Abbreviation: AuNPs, gold nanoparticles; AgNPs, silver nanoparticles; PDGF, platelet-derived growth factor; PKA, protein kinase A; miR, microRNA; VEGF, vascular endothelial growth factor; Thi, thionine; Fc-CHO, ferrocene carboxaldehyde; CSNPs, core–shell nanoparticles; CTAB, cetyltrimethylammonium bromide; PSA, prostate specific antigen; AgNCs, silver nanoclusters; CuNPs, copper nanoparticles; CuNCs, copper nanoclusters; HAT, histone acetyltransferase; MBA, 4-mercaptobenzoic acid; MPA, 3-mercaptopropanoic acid; UCNPs, upconversion nanoparticles; DPP-IV, dipeptidyl peptidase-IV; AβO, amyloid-β oligomer; hCG, human chorionic gonadotropin; biotin–FNPs, biotin–phenylalanine-assembled nanoparticles; SA, streptavidin; Fc, ferrocene; CYFRA 21-1, cytokeratin19 fragment.